DSpace Repository
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
Login
English
Türkçe
DSpace Home
→
Araştırma Çıktıları | Scopus
→
Araştırma Çıktıları | Scopus İndeksli Yayınlar Koleksiyonu
→
View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL
Akpinar, S.
;
Dogu, M.H.
;
Celik, S.
;
Ekinci, O.
;
Hindilerden, I.Y.
;
Dal, M.S.
;
Davulcu, E.A.
;
Tekinalp, A.
;
Hindilerden, F.
;
Ozcan, B.G.
;
Hacibekiroglu, T.
;
Erkurt, M.A.
;
Bagci, M.
;
Namdaroglu, S.
;
Korkmaz, G.
;
Bilgir, O.
;
Cagliyan, G.A.
;
Ozturk, H.B.A.
;
Serin, I.
;
Tiryaki, T.O.
;
Ozatli, D.
;
Korkmaz, S.
;
Ulas, T.
;
Eser, B.
;
Turgut, B.
;
Altuntas, F.
URI:
http://hdl.handle.net/11616/72304
Date:
2022
Abstract:
Introduction/Background: The emergence of novel agents targeting the B-cell receptor pathway and BCL-2 has significantly changed the therapeutic landscape of CLL. We evaluated the safety and efficacy of single-agent ibrutinib in relapsed/refractory CLL in real-world settings. Patients/Methods: A total of 200 relapsed/refractory CLL patients with a median age of 68 were included in this retrospective, multicenter, non-interventional study. Data of the study were captured from the patient charts of the participating centers. Results: The median for lines of previous chemotherapy was 2 (1-6); 62 (31.8%) patients had del17p and/or p53 mutations (del17p+/p53mut). Of the study group, 146 (75%) patients achieved at least PR, while 16 (8.7%) patients discontinued ibrutinib due to TEA. The most common drug-related adverse events were neutropenia (n: 31; 17.4%) and thrombocytopenia (n: 40; 22.3%), which were ≥ grade 3 in 9 (5%) and 5 (3.9%) patients, respectively. Pneumonia (n: 42; 23.7%) was the most common nonhematologic TEA. Atrial fibrillation (n: 5; 2.8%) and bleeding (n: 11; 6.3%) were relatively rare during the study period. Within a median follow-up period of 17 (1-74) months, 42 (21%) patients died. The estimated median OS of the study cohort was 52 months. Only the response to ibrutinib (CR/PR vs. SD/PD) was significantly associated with OS. Conclusion: Our results indicate good safety and efficacy for single-agent ibrutinib in R/R CLL in daily practice. © 2021 Elsevier Inc.
Show full item record
Files in this item
Files
Size
Format
View
There are no files associated with this item.
This item appears in the following Collection(s)
Araştırma Çıktıları | Scopus İndeksli Yayınlar Koleksiyonu
[10117]
Search DSpace
Search DSpace
This Collection
Advanced Search
Browse
All of DSpace
Communities & Collections
By Issue Date
Authors
Titles
Subjects
By Submit Date
By Type
Language
Publisher
Department
Rights
This Collection
By Issue Date
Authors
Titles
Subjects
By Submit Date
By Type
Language
Publisher
Department
Rights
My Account
Login
Register